NASDAQ:BIIB

Biogen Stock Insider Trading

Healthcare > Drug Manufacturers - General

Buy BIIB

*Your capital is at risk

$207.94

+1.66 (+0.80%)

At Close: Aug 07, 2026

Biogen Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 61.91. In total, the insiders bought 272.52K and sold 30.25K BIIB shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	61.91
● Buy	272.52K shares
● Sell	30.25K shares
72% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence Aug 04, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 61.91. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 06, 2026 Buy	Restricted Stock Unit M-Exempt	Kramer Robin Chief Financial Officer	C-Suite Officer	789 Value: $158.7K
Feb 06, 2026 Buy	Common Stock M-Exempt	Keeney Adam Head Of Corporate Development	Officer	3 278 Value: $659.5K
Feb 06, 2026 Buy	Restricted Stock Unit M-Exempt	Keeney Adam Head Of Corporate Development	Officer	3 278 Value: $659.5K
Feb 06, 2026 Sell	Common Stock F-InKind	Keeney Adam Head Of Corporate Development	Officer	994 Value: $200.0K
Feb 06, 2026 Buy	Common Stock M-Exempt	Keeney Adam Head Of Corporate Development	Officer	1 802 Value: $362.5K
Feb 06, 2026 Sell	Common Stock F-InKind	Keeney Adam Head Of Corporate Development	Officer	589 Value: $118.5K
Feb 06, 2026 Buy	Restricted Stock Unit M-Exempt	Keeney Adam Head Of Corporate Development	Officer	1 802 Value: $362.5K
Feb 06, 2026 Sell	Common Stock F-InKind	Izzar Rachid Head Of Global Product Strat.	Officer	805 Value: $161.9K
Feb 06, 2026 Buy	Common Stock M-Exempt	Izzar Rachid Head Of Global Product Strat.	Officer	3 043 Value: $612.2K
Feb 06, 2026 Sell	Common Stock F-InKind	Izzar Rachid Head Of Global Product Strat.	Officer	775 Value: $155.9K
Feb 06, 2026 Buy	Restricted Stock Unit M-Exempt	Izzar Rachid Head Of Global Product Strat.	Officer	3 043 Value: $612.2K
Feb 06, 2026 Buy	Restricted Stock Unit M-Exempt	Izzar Rachid Head Of Global Product Strat.	Officer	2 044 Value: $411.2K
Feb 06, 2026 Buy	Common Stock M-Exempt	Grogan Jane Head Of Research	Officer	1 873 Value: $376.8K
Feb 06, 2026 Sell	Common Stock F-InKind	Grogan Jane Head Of Research	Officer	584 Value: $117.5K
Feb 06, 2026 Buy	Restricted Stock Unit M-Exempt	Grogan Jane Head Of Research	Officer	1 873 Value: $376.8K
Feb 06, 2026 Sell	Common Stock F-InKind	Gregory Ginger EVP, Human Resources	Officer	1 132 Value: $227.7K
Feb 06, 2026 Sell	Common Stock F-InKind	Gregory Ginger EVP, Human Resources	Officer	666 Value: $134.0K
Feb 06, 2026 Buy	Common Stock M-Exempt	Gregory Ginger EVP, Human Resources	Officer	1 635 Value: $328.9K
Feb 06, 2026 Sell	Common Stock F-InKind	Gregory Ginger EVP, Human Resources	Officer	791 Value: $159.1K
Feb 06, 2026 Buy	Restricted Stock Unit M-Exempt	Gregory Ginger EVP, Human Resources	Officer	3 746 Value: $753.6K
Feb 06, 2026 Buy	Restricted Stock Unit M-Exempt	Gregory Ginger EVP, Human Resources	Officer	1 802 Value: $362.5K
Feb 06, 2026 Buy	Restricted Stock Unit M-Exempt	Gregory Ginger EVP, Human Resources	Officer	1 635 Value: $328.9K
Feb 06, 2026 Buy	Common Stock M-Exempt	Godbout Sean Chief Accounting Officer	Officer	517 Value: $104.0K
Feb 06, 2026 Sell	Common Stock F-InKind	Godbout Sean Chief Accounting Officer	Officer	180 Value: $36.2K
Feb 06, 2026 Buy	Restricted Stock Unit M-Exempt	Godbout Sean Chief Accounting Officer	Officer	517 Value: $104.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT BIOGEN INC.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an ad...

Read Full Profile Here